$Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study$

Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study

Hodgkin's lymphoma (HL) has no standard of care for patients who are relapsed or refractory to autologous stem-cell transplantation (ASCT). This phase II study examined safety and activity of panobinostat in this population. Panobinostat 40 mg was administered orally three times per week. The p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2012-06, Vol.30 (18), p.2197-2203
Hauptverfasser:	YOUNES, Anas, SUREDA, Anna, LE CORRE, Christophe, SHEN, Angela, ENGERT, Andreas, BEN-YEHUDA, Dina, ZINZANI, Pier Luigi, ONG, Tee-Chuan, PRINCE, H. Miles, HARRISON, Simon J, KIRSCHBAUM, Mark, JOHNSTON, Patrick, GALLAGHER, Jennifer
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adolescent Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Biological and medical sciences Disease-Free Survival Female Hematologic and hematopoietic diseases Hematopoietic Stem Cell Transplantation Hodgkin Disease - drug therapy Hodgkin Disease - therapy Humans Hydroxamic Acids - administration & dosage Hydroxamic Acids - adverse effects Indoles Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Recurrence Retreatment Treatment Failure Tumors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!